North America is expected to possess a 40% market share for the Primary Hyperoxaluria Treatment Market in 2023

Increasing awareness and diagnosis of the condition Shaping Landscape for Primary Hyperoxaluria Treatment in South & East Asia

According to a new market research report published by Future Market Insights, the global Primary Hyperoxaluria Treatment Market Demand is expected to grow at a CAGR of 8.6% during the forecast period of 2023 to 2033. The market is expected to surpass US$ 41 million in value terms by the end of the aforementioned forecast period.

Primary hyperoxaluria (PH) is a rare hereditary condition that impairs the liver's capacity to metabolise oxalate, resulting in kidney stone production and gradual kidney damage. The Primary Hyperoxaluria Treatment market consists of medications and therapies that try to reduce oxalate formation in the body, manage symptoms, and prevent problems.

Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-16885

Lumasiran (Oxlumo), an RNA interference (RNAi) therapy that works by preventing the development of the enzyme that creates oxalate in the liver, is one of the most common hyperoxaluria medicines on the market. The FDA approved the medicine in 2020 for the treatment of PH type 1 in children and adults; oxalate-degrading enzymes that can break down oxalate in the gut, reducing the amount of oxalate absorbed into the bloodstream; kidney stone management, as well as dialysis and kidney transplant.

Because of the disease's rarity, the primary hyperoxaluria therapy market is very limited, but with the approval of Lumasiran, there is a rising focus on discovering new medicines for the ailment. Dicerna Pharmaceuticals, Alnylam Pharmaceuticals, and Allena Pharmaceuticals are among the businesses presently developing PH therapies.

Market Drivers

The rising prevalence of primary hyperoxaluria is likely to be a major driving force in the Primary Hyperoxaluria Treatment market. Although the illness is rare, its prevalence has been progressively increasing in recent years.

Primary hyperoxaluria is a hereditary condition that impairs the liver's capacity to metabolise oxalate, causing kidney stones and gradual kidney damage. According to the National Institutes of Health (NIH), the estimated global prevalence of primary hyperoxaluria ranges from one in 100,000 to one in one million people.

Ask More About This Market's Geographical Distribution Along With a Detailed Analysis of the Top Regions: https://www.futuremarketinsights.com/ask-question/rep-gb-16885

Market Restraints

One of the major issues confronting the PKU medicines market is the disorder's lack of awareness and underdiagnosis. Because primary hyperoxaluria is a rare disease, there is little knowledge of it among healthcare providers and the general population. Delays in diagnosis and treatment can have a negative impact on patient outcomes.

Furthermore, discovering new medicines for rare disorders such as primary hyperoxaluria can be difficult due to a complicated and unclear regulatory environment. This can cause delays in the introduction of new medicines to the market. While there have been some recent breakthroughs in the Primary Hyperoxaluria Treatment market, there are still a number of obstacles that must be addressed in order to enhance patient outcomes and assure the development of more effective and accessible medicines.

Market Competition

Key players in the market include companies such as Competition Deep Dive, Alnylum Pharma, OxThera, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co Ltd, Genentech, along with healthcare providers and technology companies among other global players.

• In 2020, the United States Food and Drug Administration (FDA) gave the green light to Oxlumo (lumasiran) as the initial treatment for primary hyperoxaluria type 1 (PH1), a rare hereditary disorder. This groundbreaking approval is the culmination of the work of specialists and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.
• The approval of Oxlumo was a result of input from patients, treating physicians, experts, and sponsors at a patient-focused drug development meeting and through other collaborative efforts. Oxlumo's function is to reduce the production of oxalate in patients with PH1. The drug was evaluated in two separate trials in PH1 patients: a randomized, placebo-controlled trial in patients aged six years and older, and an open-label study in patients under six years old. The patients ranged in age from four months to 61 years at the start of treatment.

Purchase Now to Uncover Segment-specific Information, Identify Key Trends, Drivers, and Challenges: https://www.futuremarketinsights.com/checkout/16885

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Primary Hyperoxaluria Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

Key Segments Profiled in the Primary Hyperoxaluria Treatment Industry Survey

Type:

• Type 1
• Type 2
• Type 3

Drug Class:

• Pyridoxine
• Potassium Citrate
• Thiazides
• Orthophosphates

Route of Administration:

• Oral
• Intravenous

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies